Curriculum Vitae

europass

Europass

Cristina Poltronieri, MD

Personal Information	
Name	Cristina Poltronieri
Date of birth	May 15, 1985
Italian Fiscal Code	PLTCST85E55D653M
Address	Via del Pignalone 1/A - 06034 Foligno (PG), Italy
Telephone	+39-0742-355209
Mobile Phone	+39-349-3560057
e-mail	cristypol@libero.it
Nazionality	Italian
Languages	Italian mother tongue Good spoken and written English
Professional Experience Date, achievement	➢ From September 2017: Medical specialist (outpatient substiute) at USL Umbria 1 and 2. ➢ From January 2018: Temporary assignment as Medical specialist (Cardiologist) at USL Umbria 1. ➢ From March 2018: Temporary Assignment as Medical specialist (Cardiologist) at CSRNR, Foligno.
Educational Background Date, achievement	➢ 2004 : Secondary School Diploma in Classical Studies;Liceo Classico "F. Frezzi", Foligno (Italy) ➢ 2010: Degree in Medicine and Surgery (110/110 cum laude); University of Perugia – Faculty of Medicina e Chirurgia ➢ 2010: professional qualification in Medicine and Surgery; University of Perugia – Faculty of Medicina e Chirurgia (270/270); registration to Medical Board of Perugia (from march 14, 2011; n° 7415). ➢ From July 2012 to July 2017: postgraduate course in cardiology; University of Perugia – Faculty of Medicina e Chirurgia S.C. Cardiologia, Dipartimento Cardio-Toraco-Vascolare, Azienda Ospedaliera S. Maria, Viale Tristano di Joannuccio, 1 – 05100 Terni – Italy ➢ July 2017: Achievement of the specialization in Cardiology (50/50 cum laude)
ScientificActivity	Author of full-length articles on cardiovascular disease and evaluation of cardiovascular treatment published in leading journals including *J Hyperten, Mini Rev Med Chem, TherAdv Cardiovasc Dis, Expert Opin Drug MetabToxicol, High Blood Press CardiovascPrev, CurrCardiol Rep, Expert Opin Drug Saf, Curr Drug Saf, Expert Rev Cardiovasc Ther.*
ClinicalStudies	Involved as clinical investigator in multi-centre clinical studies and trials, including: 1) Umbria Atrial Fibrillation Registry (www.umbria-fa.it; from May 2013);

	2) Efficacy and Safety Study of F373280 (ClinicalTrials.gov Identifier: NCT01831856; from January 2014); 3) GLOBAL LEADERS (ClinicalTrials.gov Identifier: NCT01813435, from March 2015); 4) A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction (ClinicalTrials.gov Identifier: NCT02108262, from June 2015). 5)Clinical Benefits of the Closed Loop Stimulation in SinusNode(ClinicalTrials.gov Identifier:NCT02579889, from March 2017)
TechnicalSkills	Current User of Medical Instruments (ECG, echocardiography, ambulatory blood pressure monitoring,ergometric test, etc.) Current user of Computers, Internet, etc. Current users of databases and statistical packages for clinical and research purposes Medical and scientific writing
Articlesindexed in PubMed	1. Verdecchia P, Angeli F, Mazzotta G, Bartolini C, Garofoli M, Aita A, Poltronieri C, Pinzagli MG, Valecchi F, Martone S, Ramundo E, Turturiello D, Reboldi G. Impact of Chamber Dilatation on the Prognostic Value of Left Ventricular Geometry in Hypertension. J Am Heart Assoc. **2017** May 24;6(6) 2. Angeli F, Reboldi G, Poltronieri C, Lazzari L, Sordi M, Garofoli M, Bartolini C, Verdecchia P. Hyperglycemia in acute coronary syndromes: from mechanisms to prognostic implications. *Ther Adv Cardiovasc Dis*. **2015** Review;9(6):412-24. 3. Angeli F, Reboldi G, Poltronieri C, Aita A, Bartolini C, Verdecchia P.Detrimental Effects of Hyperglycemia in Acute Coronary Syndromes: from Pathophysiological Mechanisms to Therapeutic Strategies.*Mini Rev Med Chem*.**2015**;15(14):1164-73. Review. 4. Angeli F, Reboldi G, Poltronieri C, Stefanetti E, Bartolini C, Verdecchia P; MAVI Investigators..The prognostic legacy of left ventricular hypertrophy: cumulative evidence after the MAVI study.*J Hypertens*.**2015** Nov;33(11):2322-30. 5. Verdecchia, P.; Angeli, F.; Bartolini, C.; De Filippo, V.; Aita, A.; Di Giacomo, L.; Poltronieri, C.; Lip, G.Y.; Reboldi, G. Safety and efficacy of non-vitamin k oral anticoagulants in non-valvular atrial fibrillation: A bayesian meta-analysis approach. *Expert Opin Drug Saf* **2015**, *14*, 7-20. 6. Angeli, F.; Reboldi, G.; Poltronieri, C.; Stefanetti, E.; Bartolini, C.; Verdecchia, P.; Investigators, M. The prognostic legacy of left ventricular hypertrophy: Cumulative evidence after the mavi study. *J Hypertens* **2015**. 7. Angeli, F.; Reboldi, G.; Poltronieri, C.; Lazzari, L.; Sordi, M.; Garofoli, M.; Bartolini, C.; Verdecchia, P. Hyperglycemia in acute coronary syndromes: From mechanisms to prognostic implications. *Ther Adv Cardiovasc Dis* **2015**.

8. Angeli, F.; Reboldi, G.; Poltronieri, C.; Aita, A.; Bartolini, C.; Verdecchia, P. Detrimental effects of hyperglycemia in acute coronary syndromes: From pathophysiological mechanisms to therapeutic strategies. *Mini Rev Med Chem* **2015**.
9. Angeli, F.; Verdecchia, P.; Poltronieri, C.; Bartolini, C.; de Filippo, V.; D'Ambrosio, C.; Reboldi, G. Ambulatory blood pressure monitoring in the elderly: Features and perspectives. *Nutr Metab Cardiovasc Dis* **2014**, *24*, 1052-1056.
10. Angeli, F.; Reboldi, G.; Poltronieri, C.; Bartolini, C.; D'Ambrosio, C.; de Filippo, V.; Verdecchia, P. Clinical utility of ambulatory blood pressure monitoring in the management of hypertension. *Expert Rev Cardiovasc Ther* **2014**, *12*, 623-634.
11. Angeli, F.; Reboldi, G.; Poltronieri, C.; Angeli, E.; De Filippo, V.; Crocetti, A.; Bartolini, C.; D'Ambrosio, C.; Verdecchia, P. Efficacy and safety profile of aliskiren: Practical implications for clinicians. *Curr Drug Saf* **2014**, *9*, 106-117.
12. Angeli, F.; Verdecchia, P.; Pascucci, C.; Poltronieri, C.; Reboldi, G. Pharmacokinetic evaluation and clinical utility of azilsartan medoxomil for the treatment of hypertension. *Expert Opin Drug Metab Toxicol* **2013**, *9*, 379-385.
13. Angeli, F.; Reboldi, G.; Mazzotta, G.; Poltronieri, C.; Verdecchia, P. Safety and efficacy of aliskiren in the treatment of hypertension: A systematic overview. *Expert Opin Drug Saf* **2012**, *11*, 659-670.
14. Angeli, F.; Reboldi, G.; Mazzotta, G.; Poltronieri, C.; Garofoli, M.; Ramundo, E.; Biadetti, A.; Verdecchia, P. Safety and efficacy of aliskiren in the treatment of hypertension and associated clinical conditions. *Curr Drug Saf* **2012**, *7*, 76-85.
15. Angeli, F.; Reboldi, G.; Mazzotta, G.; Garofoli, M.; Ramundo, E.; Poltronieri, C.; Verdecchia, P. Fixed-dose combination therapy in hypertension: Cons. *High Blood Press Cardiovasc Prev* **2012**, *19*, 51-54.
16. Angeli, F.; Reboldi, G.; Garofoli, M.; Ramundo, E.; Poltronieri, C.; Mazzotta, G.; Ambrosio, G.; Verdecchia, P. Atrial fibrillation and mortality in patients with acute myocardial infarction: A systematic overview and meta-analysis. *Curr Cardiol Rep* **2012**, *14*, 601-610.

The undersigned person is aware of legal and penal implications (Italian law 15/68, art. 26) of any false statement eventually contained in this document. The undersigned person authorize diffusion of information included in this document as outlined by the Italian law (196/03).

Date: 7 March 2018

Cristina Poltronieri